Modulatory effects of Xihuang Pill on lung cancer treatment by an integrative approach - 27/10/20
pages | 9 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Xihuang Pill inhibited tumour growth without evident toxicity to internal organs in the Lewis lung cancer (LLC) -incubated mouse model. |
• | 11 differentially expressed metabolites that could reflect the effect of Xihuang Pill in lung cancer treatment were identified using untargeted metabolomics analysis. |
• | The regulatory role of Xhuang Pill treatment for lung cancer by reversing potential metabolites associated with amino acids metabolism. |
• | 4 biomarkers were regulated by 107 components of Xihuang Pill acting directly on 13 key targets that associated with cancer. |
Abstract |
Lung cancer has a rapidly increasing incidence and remains the highest ranked cancer in terms of mortality worldwide. Xihuang Pill(XHW), a famous four-herb traditional Chinese formulation, has been used to treat lung cancer in China for more than 100 years. It is usually prescribed as a complementary and alternative medicine for cancer therapy. However, the main active ingredients of XHW that treat lung cancer and their regulatory effects remain unclear. Here, we revealed modulatory effects effects of XHW on lung cancer in a mouse model of Lewis lung cancer (LLC) by a comprehensive strategy combining network pharmacology with metabolomics. The results demonstrated that XHW inhibited tumour growth in this model. Additionally, 11 differentially expressed metabolites were identified in the XHW group compared to those in the model group or normal group by untargeted metabolomics. They were enriched in amino acid-related metabolic pathways, and the top three pathways were phenylalanine metabolism; phenylalanine, tyrosine and tryptophan biosynthesis; and aminoacyl-tRNA biosynthesis. A total of 107 active components derived from Niuhuang, Shexiang, Ruxiang and Moyao, directly acted on 13 important targets (NR3C2, AKR1D1, MPO, PNP, NT5E, TAAR1, ADRB2, ADRB1, ADRA1A, ADRA2B, ADRA2A, MAOA and MAOB) to regulate 4 metabolites (L-phenylalanine, l-adrenaline, corticosterone and guanosine). Our results suggested that the key metabolites of XHW involved in the treatment of lung cancer were regulated by a multi-component and multi-target interaction network. This research elucidated the modulatory effect and therapeutic advantages of XHW treatment for lung tumours through an integrated approach.
Le texte complet de cet article est disponible en PDF.Keywords : Xihuang Pill, Lung cancer, Metabolomics, Network pharmacology, Modulatory effects
Plan
Vol 130
Article 110533- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?